Amelioration of the development of cataracts and other ophthalmic diseases
AssigneeOthera Holding, Inc.
InventorsWilliam L. Matier, Ghanshyam Patil
Life of this patent
Estimating the term…
Abstract
Ophthalmically acceptable compositions used in arresting the development of cataracts or macular degeneration comprising a pharmaceutically acceptable carrier or diluent and a compound having the formula: where R1 and R2 are, independently, H or C1 to C3 alkyl; R3 and R4 are, independently C1 to C3 alkyl; and where R1 and R2, taken together, or R3 and R4, taken together, or both may be cycloalkyl; R5 is H, OH, or C1 to C6 alkyl; R6 is or C1 to C6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl; R7 is C1 to C6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl or where R6 and R7, or R5, R6 and R7, taken together, form a carbocycle or heterocycle having from 3 to 7 atoms in the ring.
Claims23
A composition comprising a pharmaceutically acceptable carrier or diluent and a compound having the formula:
- where R1 and R2 are, independently, H or C1 to C3 alkyl;
- R3 and R4 are, independently, C1 to C3 alkyl;
- and
- where R1 and R2, taken together, or R3 and R4, taken together, or both may be cycloalkyl;
- R5 is H, OH, or C1 to C6 alkyl;
- R6 is C1 to C6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl;
- R7 is C1 to C6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl;
- or where R6 and R7 form a cycloalkyl having from 3 to 7 atoms in the ring.
Dependencies are inferred from the claim text.